Updated Data Matrix Available

Market Value | Market Volume | Epidemiology | Clinical Trials | Patent Landscape | Regulatory Approvals

Global Recombinant Proteins Market $4.7 Billion by 2029

The global market for recombinant proteins projected to reach $4.7 billion by 2029, expanding at a double-digit CAGR of 11.7% over the forecast period, driven by increasing prevalence of various types of cancer, neurological diseases, metabolic disorders, infectious diseases, genetic disorders, and immune diseases, as well as growing R&D activities in biosimilars, biologics, and recombinant proteins production worldwide.

  • The market for recombinant pharmaceutical proteins is expanding rapidly. Indeed, nearly all pharmaceutical companies with a market capitalization value of more than $US 10 billion report that their revenue share from such products is growing faster than the share from small-molecule drugs.
Global Recombinant Proteins Market

Recombinant proteins are large and complex molecules, whose therapeutic activity highly depends on their structure. Formulation of biopharmaceuticals is considered important in stabilizing protein conformation, promoting its efficacy, and preventing safety concerns, such as immunogenicity.

  • Currently, the rational design of formulations is possible due to the availability of several techniques for molecule characterization and an array of both well-known and new excipients. The high-throughput technologies and quality by design approaches are trending and have been contributing to the advancement of the field.
    • There has been an increasing demand for strategies that improve protein delivery and more comfortable administration to the patients, especially with the arising of recombinant proteins in the treatment of chronic diseases, such as autoimmune conditions or heart diseases.
  • However, the challenges in production pf recombinant proteins include achieving cell density, protein expression, separations of cells and protein, protein purification, and segmentation of protein production into smaller quantities with the evolution of personalized medicine and products designed for increasingly small patient populations.

The global market for recombinant proteins research report provides market size ($million 2019 to 2029), market share analysis, growth trends and forecast (CAGR%, 2023 to 2029).

The global market for recombinant proteins segmented by product [cytokines and growth factors (interferons, interleukins, others)], antibodies, immune checkpoint inhibitors, virus antigens, enzymes (kinases, metabolic enzymes, others), recombinant regulatory protein, hormones, others; production services], application [drug discovery and development, therapeutics, (biologics, vaccines, cell and gene therapies, others), research, others], by end user (academic and research institutes, diagnostic laboratories, pharma and biotechnology companies, others), host cell (mammalian systems, insect cells, yeast and fungi, bacterial cells, others}, and geography.

  • Based on the products and services, the recombinant protein products segment accounted for the largest share of the total market. Recombinant proteins that have survived the challenges of process development and clinical trials are becoming blockbuster medical products.
    • Growth factors, enzymes and antibodies are being improved by mutational approaches, fused with other proteins, and even chemically modified in vitro. The future protein products might include cancer vaccines and therapies for a variety of genetic diseases, but alternative treatments involving gene therapy or small synthetic compounds are likely to provide competition.
      • With the continuing expansion of the biotherapeutics market aided by the commercial successes of antibody therapeutics and emerging biosimilars, the demand for proteins derived from mammalian cells continues to grow and the biopharmaceutical industry is faced with the challenge of efficiently producing these proteins in large quantities.
  • In terms of applications, the therapeutics segment dominated the total market revenue share for recombinant protein products, as recombinant therapeutic proteins have become increasingly important over the past ten years.
    • The development of long-acting recombinant proteins with long half-life requires low frequent dose or injection, which results in higher patient compliance in recent years. The use of recombinant DNA methods to produce large quantities of protein for therapeutic uses has revolutionized medicine.
      • Industrial challenges for manufacture of biotherapeutic proteins are related to the characteristics of these proteins and the increasing quantities required to address needs of patients, worldwide.
        • The number of recombinant proteins molecules and their applications have significantly expanded over the last 15-20 years, together with the quantities used to address specific indications.
  • Among the end users, the pharma and biotechnology companies segment led the global market for recombinant proteins, as these recombinant protein product needs unique settings or standardizations for large-scale production and purification.
    • The central pillar of the biotechnology and pharmaceutical industries continues to be the development of biological drug products manufactured from engineered mammalian cell lines.
      • Only the large-scale production setup can provide the growing demand, and being cost-effective, as the usage of recombinant DNA technology for large-scale production of proteins requires ample amount of time, labor, and resources, but it also offers many opportunities for economic growth.
        • The tools of genetic engineering are utilized to produce the proteins of human origin in bacteria, fungi, insect, or mammalian host.
  • By the host cell types, the mammalian systems segment accounted for the largest revenue share of the total recombinant protein products market, followed by bacterial cells, and yeast and fungus segments, respectively. In recent years, the production of recombinant pharmaceutical proteins in heterologous systems has increased significantly.
    • Most applications involve complex proteins and glycoproteins that are difficult to produce, thus promoting the development and improvement of a wide range of production platforms. The industry has focused on a small number of production platforms based on the bacterium Escherichia coli, several species of yeast, and a selection of insect and mammalian cell lines, which have been developed and improved in line with current good manufacturing practice (cGMP).
      • The mammalian cell lines have emerged as a new and powerful alternative for the production of human therapeutic proteins because this expression system is expected to produce recombinant proteins with post translation modifications more similar to their natural counterpart and reduce the potential immunogenic reactions against nonhuman epitopes.
        • These cells have shown efficient production in laboratory scale and represent an important tool for the pharmaceutical industry.

The global market for recombinant proteins research report is further segmented by geography into North America (U.S., Canada), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), Latin America (Brazil, Mexico, Rest of LA), and Rest of the World.

In addition, the global market for recombinant proteins report provides the detailed market landscape (market drivers, restraints, opportunities), market attractiveness analysis, and market profitability analysis by key products and regions or countries. The report also tracks the major competitors operating in the global market by company overview, financial snapshot, major products, technologies, services offered and recent developments.

Major competitors operating in the global market for recombinant proteins and profiled in this report include Abcam plc, Abnova Corporation, Bio-Rad Laboratories, Inc., Enzo Life Sciences, Inc., GenScript, Merck & Co., Inc., Proteintech Group, Inc., R&D Systems, Inc., RayBiotech Life, Inc., STEMCELL Technologies, Inc., Sino Biological, Inc., and Thermo Fisher Scientific, Inc.

  • Product and Services
    • Product
      • Cytokines and Growth Factors
        • Interferons (IFNs)
        • Interleukins (ILs)
        • Others
      • Antibodies
      • Immune Checkpoint Inhibitors
      • Virus Antigens
      • Enzymes
        • Kinases
        • Metabolic Enzymes
        • Others
      • Recombinant Regulatory Proteins
      • Hormones
      • Others
    • Production Services
  • Application
    • Drug Discovery and Development
    • Therapeutics
      • Biologics
      • Vaccines
      • Cell and Gene Therapies
      • Others
    • Research
    • Others
  • End User
    • Academic and Research Institutes
    • Diagnostic Laboratories
    • Pharma and Biotechnology Companies
    • Others
  • Host Cell
    • Mammalian Systems
    • Insect Cells
    • Yeast and Fungi
    • Bacterial Cells
    • Others
  • Geography
    • North America (U.S., Canada)
    • Europe (U.K., Germany, France, Italy, Spain, Rest of EU)
    • Asia Pacific (Japan, China, India, Rest of APAC)
    • Latin America (Brazil, Mexico, Rest of LA)
    • Rest of the World
  • Company Profiles
    • Abcam plc
    • Abnova Corporation
    • Bio-Rad Laboratories, Inc.
    • Enzo Life Sciences, Inc.
    • GenScript
    • Merck & Co., Inc.
    • Proteintech Group, Inc.
    • R&D Systems, Inc.
    • RayBiotech Life, Inc.
    • STEMCELL Technologies, Inc.
    • Sino Biological, Inc.
    • Thermo Fisher Scientific, Inc.

To request Table of Contents and Sample Pages of this report:
https://www.ihealthcareanalyst.com/report/recombinant-proteins-market/

Related publications:

    Request ToC/Sample information for this market analysis

    Full Name*

    Company Email*

    Phone Number* [Please add country code]

    Subject*

    Message*

    Secure Online Payment

    iHealthcareAnalyst, Inc.

    Contact Address

    US Office: 2109, Mckelvey Hill Drive, Maryland Heights, MO 63043, United States
    Phone: +1 (314) 315-4764
    India Office: 5, Shilpa Chambers, Opp. J. M. Road, Shivajinager, Pune 411005, India
    Phone: +91 (20) 25898524
    Email: sales@ihealthcareanalyst.com